Keryx Biopharmaceuticals (NASDAQ: KERX) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.
This table compares Keryx Biopharmaceuticals and Agile Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for Keryx Biopharmaceuticals and Agile Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Keryx Biopharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 44.93%. Agile Therapeutics has a consensus target price of $10.20, indicating a potential upside of 122.22%. Given Agile Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Agile Therapeutics is more favorable than Keryx Biopharmaceuticals.
Risk and Volatility
Keryx Biopharmaceuticals has a beta of 5.07, meaning that its stock price is 407% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500.
Institutional and Insider Ownership
65.1% of Keryx Biopharmaceuticals shares are owned by institutional investors. Comparatively, 67.5% of Agile Therapeutics shares are owned by institutional investors. 2.6% of Keryx Biopharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Agile Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Keryx Biopharmaceuticals and Agile Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Keryx Biopharmaceuticals||$31.98 million||18.01||-$161.09 million||($1.50)||-3.22|
|Agile Therapeutics||N/A||N/A||-$28.74 million||($0.92)||-4.99|
Agile Therapeutics has higher revenue, but lower earnings than Keryx Biopharmaceuticals. Agile Therapeutics is trading at a lower price-to-earnings ratio than Keryx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Agile Therapeutics beats Keryx Biopharmaceuticals on 10 of the 12 factors compared between the two stocks.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.